



1647

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of:  
Lu et al.

Serial No: 09/499,526

Filed: February 10, 2000

For: METHODS AND REAGENTS FOR  
TREATING GLUCOSE  
METABOLIC DISORDERS

Attorney Docket No. CIBT-P01-058

JUL 09 2003

Art Unit: 1647

Examiner: R. DeBerry

RECEIVED


JUL 09 2003  
TECH CENTER 1600/2900

**CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)**

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

on July 2, 2003

Date

  
Brent LaBarge

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**TRANSMITTAL OF SEQUENCE LISTING IN PAPER FORM IN  
COMPLIANCE WITH 37 C.F.R. §1.821(c)**

Sir:

Responsive to the sequence listing objections raised in the Office Communication of June 2, 2003, Applicants submit herewith a paper copy of the sequence listing in accordance with 37 C.F.R. §1.821(c).

As required by 37 C.F.R. § 1.821(f), Applicants' Agent hereby states that the contents of the "Sequence Listing" in paper form filed herewith and the C.R.F. received by the office via the Electronic Filing System on June 26, 2003 are the same.

Date: July 2, 2003

**Customer No: 28120**  
Docketing Specialist  
Ropes & Gray  
One International Place  
Boston, MA 02110  
Phone: 617-951-7000  
Fax: 617-951-7050

Respectfully Submitted,

  
Melissa Rones  
Reg. No: P54,408



## AMINO ACID AND/OR NUCLEOTIDE SEQUENCE LISTING SUBMISSION

Electronic Version v13

Stylesheet Version v01

RECEIVED

JUL 09 2003

TECH CENTER 1600/2900

This is a request for filing the electronic Computer Readable Form copy of a sequence listing via the Electronic Filing System for a patent application under 37 CFR 1.821-1.825 instead of via one of the physical media specified in 37 CFR 1.824(c).

This communication has an attached file which is an electronic copy of the amino acid and/or nucleotide sequence listing for the previously mentioned United States patent application.

The electronic copy submitted herewith is the Computer Readable Form (CRF), as required by 1.821(e).

Any applicable fees associated with the filing of the electronic copy have been paid.

This submission does not go beyond the disclosure of the application as originally filed (i.e., contains no new matter). It may be in addition to an original CRF, filed to comply with the sequence rules.

This submission in electronic form comprises only the CRF of 37 CFR 1.821(e). I acknowledge that I am responsible for all additional requirements of amino acid and/or nucleotide sequence listing submissions as specified in 37 CFR 1.821 - 1.825.

This submission does not go beyond the disclosure of the application as originally filed (i.e., contains no new matter), and/or is in addition to an original CRF filed to comply with the sequence rules. If not made to comply with an originally filed CRF, it is identical to the sequences disclosed in the application as originally filed and/or the paper copy of the sequence listing as originally filed.

I hereby certify that this correspondence is being transmitted to the United States Patent and Trademark Office on the following date: 2003-06-26

Name: David P. Halstead  
Electronic Signature Mark: DYH

Attachment description: Substitute CRF Biosequence

Compression software used:

RECEIVED

JUL 09 2003

TECH CENTER 1600/2900